Literature DB >> 11104748

Aerosol gene transfer with inducible nitric oxide synthase reduces hypoxic pulmonary hypertension and pulmonary vascular remodeling in rats.

W Budts1, P Pokreisz, Z Nong, N Van Pelt, H Gillijns, R Gerard, R Lyons, D Collen, K D Bloch, S Janssens.   

Abstract

BACKGROUND: Nitric oxide (NO) is a potent vasodilator with an important role in the regulation of pulmonary vascular tone. The effects of NO synthase (NOS) gene transfer on pulmonary vascular remodeling associated with hypoxic pulmonary hypertension are unknown. METHODS AND
RESULTS: We aerosolized 3 x 10(9) pfu of an adenoviral vector containing inducible NOS gene (AdNOS2), constitutive NOS3 gene (AdNOS3), or no transgene (AdRR5) into rat lungs. Exhaled NO levels, monitored with chemiluminescence, were higher in AdNOS2-infected rats than in AdNOS3- and AdRR5-infected rats (at 3 days, 33+/-6 ppb, n=9, versus 17+/-4, n=9, and 6+/-2 ppb, n=3, P:<0.05 for both). Exposure to FIO(2) 0.10 for 7 days increased pulmonary artery pressure from 19+/-4 mm Hg (baseline) to 27+/-1 and 26+/-2 mm Hg in AdNOS3- and AdRR5-infected rats, respectively, but only to 21+/-1 mm Hg in AdNOS2-infected animals (P:<0.05). After 7 days of hypoxia, total pulmonary resistance in AdRR5- and AdNOS3-infected rats was significantly higher than in AdNOS2-infected animals (0.41+/-0.05 and 0.39+/-0.07 versus 0.35+/-0. 03 mm Hg. mL(-)(1). min(-)(1), respectively, P:<0.05). Right ventricular hypertrophy was reduced in AdNOS2-infected rats [right ventricular/(left ventricular+septal) weight, 0.19+/-0.10 versus 0. 28+/-0.10 and 0.32+/-0.10 in AdRR5- and AdNOS3-infected rats, respectively, P:<0.05]. The percentage of muscularized precapillary pulmonary resistance vessels was also significantly decreased (18+/-4% versus 25+/-8% and 30+/-5% in AdRR5- and AdNOS3-infected rats, P:<0.05).
CONCLUSIONS: Aerosol NOS2 gene transfer increases pulmonary NO production and significantly reduces hypoxic pulmonary hypertension and pulmonary vascular remodeling. Aerosol NOS2 gene transfer may be a promising strategy to target pulmonary vascular disorders.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11104748     DOI: 10.1161/01.cir.102.23.2880

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  16 in total

Review 1.  How valid are animal models to evaluate treatments for pulmonary hypertension?

Authors:  Maria E Campian; Maxim Hardziyenka; Martin C Michel; Hanno L Tan
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-09       Impact factor: 3.000

2.  Effect of adenovirus-mediated gene transfer of nitric oxide synthase on vascular reactivity of rat isolated pulmonary arteries.

Authors:  Leifu Jiang; Rozenn Quarck; Stefan Janssens; Peter Pokreisz; Maurits Demedts; Marion Delcroix
Journal:  Pflugers Arch       Date:  2006-01-11       Impact factor: 3.657

3.  Cytosolic phospholipase A(2) in hypoxic pulmonary vasoconstriction.

Authors:  Fumito Ichinose; Roman Ullrich; Adam Sapirstein; Rosemary C Jones; Joseph V Bonventre; Charles N Serhan; Kenneth D Bloch; Warren M Zapol
Journal:  J Clin Invest       Date:  2002-06       Impact factor: 14.808

4.  Adenoviral gene transfer of endothelial nitric-oxide synthase (eNOS) partially restores normal pulmonary arterial pressure in eNOS-deficient mice.

Authors:  Hunter C Champion; Trinity J Bivalacqua; Stanley S Greenberg; Thomas D Giles; Albert L Hyman; Philip J Kadowitz
Journal:  Proc Natl Acad Sci U S A       Date:  2002-09-17       Impact factor: 11.205

5.  Residual pulmonary vasoreactivity to inhaled nitric oxide in patients with severe obstructive pulmonary hypertension and Eisenmenger syndrome.

Authors:  W Budts; N Van Pelt; H Gillyns; M Gewillig; F Van De Werf; S Janssens
Journal:  Heart       Date:  2001-11       Impact factor: 5.994

6.  Intratracheal Gene Delivery of SERCA2a Ameliorates Chronic Post-Capillary Pulmonary Hypertension: A Large Animal Model.

Authors:  Jaume Aguero; Kiyotake Ishikawa; Lahouaria Hadri; Carlos G Santos-Gallego; Kenneth M Fish; Erik Kohlbrenner; Nadjib Hammoudi; Changwon Kho; Ahyoung Lee; Borja Ibáñez; Ana García-Alvarez; Krisztina Zsebo; Bradley A Maron; Maria Plataki; Valentin Fuster; Jane A Leopold; Roger J Hajjar
Journal:  J Am Coll Cardiol       Date:  2016-05-03       Impact factor: 24.094

7.  Heterozygous deficiency of hypoxia-inducible factor-2alpha protects mice against pulmonary hypertension and right ventricular dysfunction during prolonged hypoxia.

Authors:  Koen Brusselmans; Veerle Compernolle; Marc Tjwa; Michael S Wiesener; Patrick H Maxwell; Désiré Collen; Peter Carmeliet
Journal:  J Clin Invest       Date:  2003-05       Impact factor: 14.808

8.  Intratracheal gene transfer of adrenomedullin using polyplex nanomicelles attenuates monocrotaline-induced pulmonary hypertension in rats.

Authors:  Mariko Harada-Shiba; Itaru Takamisawa; Kanjiro Miyata; Takehiko Ishii; Nobuhiro Nishiyama; Keiji Itaka; Kenji Kangawa; Fumiki Yoshihara; Yujiro Asada; Kinta Hatakeyama; Noriya Nagaya; Kazunori Kataoka
Journal:  Mol Ther       Date:  2009-03-31       Impact factor: 11.454

Review 9.  The role of the NO axis and its therapeutic implications in pulmonary arterial hypertension.

Authors:  Evangelos D Michelakis
Journal:  Heart Fail Rev       Date:  2003-01       Impact factor: 4.214

10.  HIF2α-arginase axis is essential for the development of pulmonary hypertension.

Authors:  Andrew S Cowburn; Alexi Crosby; David Macias; Cristina Branco; Renato D D R Colaço; Mark Southwood; Mark Toshner; Laura E Crotty Alexander; Nicholas W Morrell; Edwin R Chilvers; Randall S Johnson
Journal:  Proc Natl Acad Sci U S A       Date:  2016-07-18       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.